Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xenon Pharmaceuticals excels in epilepsy treatment with strong IP strategy

Xenon Pharmaceuticals demonstrated strong performance and promising efficacy data for XEN1101 in epilepsy treatment, supported by a robust IP strategy and CNS penetration.
While facing challenges in patient enrollment and rising expenses, the company is exploring new therapeutic areas and potential milestone payments through partnerships.
Opportunities lie in expanding XEN1101's market reach, establishing a leadership position in epilepsy treatment, and navigating uncertainties in pediatric indications and generic competition.

Xenon Pharmaceuticals advances epilepsy program amid financial stability and challenges

Xenon Pharmaceuticals showcased progress in their epilepsy program and financial stability, while addressing challenges in enrollment dynamics and competitive pressures.
The company's focus on managing R&D expenses and upcoming milestones reflects a strategic approach to advancing their clinical programs.
Opportunities in the epilepsy market and ongoing formulation development for pediatric patients position Xenon for potential growth and innovation.

Xenon Pharmaceuticals excels in trials and finances, eyes global expansion

Xenon Pharmaceuticals showcases strong performance in key trials and financial stability, supported by positive market reception and strategic leadership additions.
While facing challenges in trial completion and enrollment trends, the company has opportunities to expand market reach, innovate in treatment approaches, and explore global partnerships.
Overall, Xenon's focus on advancing novel therapies for neurological disorders positions it well for future growth and success in the competitive pharmaceutical landscape.

Xenon Pharmaceuticals advances epilepsy and MDD treatments, poised for growth

Xenon Pharmaceuticals showcased strong performance in advancing XEN1101 for epilepsy and MDD treatments, backed by extensive data and strategic partnerships.
While facing challenges in enrollment timelines and technical complexities, the company is well-positioned financially and strategically for future growth.
Opportunities abound in addressing unmet needs, expanding drug applications, and advancing new molecules into clinical development.
Overall, Xenon Pharmaceuticals' Q3 earnings call highlighted a promising outlook for drug development and market positioning.

Xenon Pharmaceuticals excels in Q4, poised for growth in epilepsy and MDD

Xenon Pharmaceuticals showcased strong financials, program advancements, and market insights in Q4 2023, positioning the company well for future growth.
The company's focus on safety, tolerability, and efficacy in MDD treatment, along with leveraging learnings across programs, demonstrates strategic foresight.
While facing challenges in R&D spend allocation and regulatory discussions, Xenon can capitalize on opportunities for operational efficiency and market expansion.
Investor interest in Xenon's pipeline and the potential of its programs in epilepsy and MDD highlight a promising trajectory for the company.

Xenon Pharmaceuticals reports strong Q1 performance and addresses market needs

Xenon Pharmaceuticals is well-positioned with a strong financial base and promising pipeline.
The company faces challenges in conducting well-powered MDD trials and addressing market needs.
Opportunities lie in the substantial unmet need in the major depressive market and azetukalner's potential benefits.
Strategic planning and FDA alignment support Xenon's progress in key therapeutic areas.

Xenon Pharmaceuticals excels in Q3, poised for groundbreaking treatments

Xenon Pharmaceuticals demonstrated strong financial performance and progress in developing azetukalner for epilepsy and major depressive disorder.
Confidence in the lead product's potential for groundbreaking treatments was evident, supported by ongoing outreach efforts and future milestones.
While facing challenges in addressing complex analyst inquiries and navigating regulatory requirements, Xenon Pharmaceuticals is well-positioned to capitalize on opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study.

Canada's Xenon Pharma's depression drug fails to meet main goal in study

VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder, or MDD. Summary of Efficacy Data The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

XEN1101 shows clinical promise in epilepsy and MDD, with Phase 3 trials critical for its broader efficacy evaluation. Financially, Xenon faces a stark YOY revenue drop and rising R&D costs but maintains strong liquidity and cash runway. Market sentiment is cautiously optimistic, balancing XEN1101's clinical potential with financial challenges and competitive landscape.

Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Danielle Brill - Raymond James Tim Lugo - William Blair Operator Hello, thank you for standing by. And welcome to Xenon Pharmaceuticals Incorporated Third Quarter 2023 Earnings Conference Call.

Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript

Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder  on track for late November to mid-December

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals appears undervalued heading into a pivotal phase two MDD trial readout due by the end of November. If XEN-1101 shows either a trend towards improvement or hits the primary endpoint, then it would translate into a massive boon for its sales potential in treating epilepsy. I would assign the stock a buy rating, with a $51 price target, based off on modest assumptions.

Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, November 8, 2023.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy. Importantly, the efficacy and safety findings of this clinical trial supported the further clinical development in epilepsy of XEN1101, which is currently being evaluated in Phase 3 clinical trials in patients with focal onset seizures (FOS) and primary generalized tonic-clonic seizures.

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Jefferies Inaugural Biotech CNS/Neuro Summit to be held on October 11, 2023.

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen's 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023.

Xenon Pharmaceuticals to Present at TD Cowen's 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) (AIM: POLX), a specialist in advanced magnetic resonance imaging (MRI) for the lungs, has announced a strategic partnership with VIDA Diagnostics, a clinical imaging intelligence firm. The collaboration aims to enhance the Polarean xenon 129 MRI platform for accelerated clinical and research applications.

Polarean Imaging partners up to enhance potential of Xenon 129 MRI technology

New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Wells Fargo 2023 Healthcare Conference to be held September 6-8, 2023.

Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference

Xenon Pharmaceuticals has a strong cash position of $652.2M and an estimated cash runway of approximately 3.11 years. The company's financial health is commendable, but widening net losses and escalating R&D expenses may necessitate external financing in the future. The X-NOVA Phase 2 study for Major Depressive Disorder (MDD) and the XEN1101 Phase 3 epilepsy program are key milestones to watch for potential commercial success.

Xenon Is Well-Funded Heading Into Key Readouts

The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Dr. Chris Kenney - CMO Dr. Chris Von Seggern - Chief Commercial Officer Conference Call Participants Tessa Romero - J.P. Morgan Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Danielle Brill - Raymond James Laura Chico - Wedbush Securities Mohit Bansal - Wells Fargo Elaine Kim - Cantor Fitzgerald Tim Lugo - Williams Blair Operator Good afternoon ladies and gentlemen, and thank you for standing by.

Xenon Pharmaceuticals Inc. (XENE) Q2 2023 Earnings Call Transcript

Xenon Pharmaceuticals (XENE) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.55 per share a year ago.

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder  with topline data expected in late November to mid-December

Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover. Dr. Cannon has more than 30 years of experience in the pharmaceutical industry, where she served in business and commercial leadership roles at Merck and Co., UCB, Otsuka and Roivant. Mr. Gover served as founding Chief Executive Officer and as a director of GW Pharmaceuticals from inception in 1999 until its sale to Jazz Pharmaceuticals for $7.2 billion in May 2021 and brings nearly twenty-five years of experience in leadership positions in the biotechnology industry with a focus on epilepsy.

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, August 9, 2023.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.

Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 Jefferies Healthcare Conference taking place June 7-9, 2023 in New York, NY.

Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference

In Q1 2023, Xenon had $687.3 million in cash and marketable securities, down from $720.8 million in Q4 2022. They anticipate sufficient funding for operations until 2026. XEN1101, a leading candidate for Major Depressive Disorder treatment, could bring market differentiation and increased valuation if successful. Data release shifted from Q3 to Q4.

News for Xenon Pharmaceuticals Stock (XENE)